Medimmune Limited

Wyeth

Elan Pharma International Limited

Albert George Thom

Geertruida Machteld Veldman

Ralph Raymond Minter

Davinder Gill

Jing Li

Lynette A Fouser

David C Lowe

Viia Valge-Archer

Caroline S Russell

Suzanne E Cohen

Andrew Grier Buchanan

Matthew Alexander Sleeman

Philip Bland-Ward

Fraser Welsh

Jon Eric Hawkinson

Ruth Franks

Celia Patricia Hart

Carl Anthony Matthews

Lutz Jermutus

Darren Schofield

David Llewellyn Rees

Jonathan P Hatcher

Lorraine Irving

Peter Cariuk

Matthew Robinson

Catherine Huntington

Carl Innes Webster

Josquin Nys

Aidan Riley

Fraser Ewing Welsh

Davinder S Gill

Philip Antony Bland-Ward

Jon Hawkinson

The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.

Therapeutic binding molecules

The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.

Blood brain barrier transport molecules and uses thereof

Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.

Methods of treating neuropathic pain with specific binding members for NGF

Specific binding members for NGF

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Nucleic acid encoding antibody to human IL-22

Antibodies to human IL-22

Antibodies against human IL-22 and uses therefor

Growing community of inventors

Cambridge, United Kingdom

Albert George Thom